|
Recruiting
|
NCT05383196 -
Onvansertib + Paclitaxel In TNBC
|
Phase 1/Phase 2 |
|
Completed
|
NCT02371174 -
Post-Marketing Surveillance Study of Eribulin on the Status and Factors for the Development of Peripheral Neuropathy in Japan.
|
|
|
Completed
|
NCT02225470 -
Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
|
Phase 3 |
|
Recruiting
|
NCT05173103 -
Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer
|
|
|
Active, not recruiting
|
NCT04448886 -
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
|
Phase 2 |
|
Not yet recruiting
|
NCT06351332 -
A Phase I/II Single-arm Trial of Azenosertib (ZN-c3) Combined With Carboplatin and Pembrolizumab in Patients With Metastatic Triple-negative Breast Cancer (ZAP-IT)
|
Phase 1/Phase 2 |
|
Not yet recruiting
|
NCT04498793 -
Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer
|
Phase 2 |
|
Completed
|
NCT01705691 -
Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer
|
Phase 2 |
|
Terminated
|
NCT01368263 -
Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer
|
Phase 2 |
|
Recruiting
|
NCT04576143 -
Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer
|
Phase 2/Phase 3 |
|
Completed
|
NCT05054374 -
A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer
|
Phase 1/Phase 2 |
|
Recruiting
|
NCT05467891 -
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
|
Phase 2 |
|
Recruiting
|
NCT04660435 -
To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer
|
|
|
Completed
|
NCT02015559 -
Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus
|
Phase 2 |
|
Completed
|
NCT04504916 -
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002)
|
Phase 2 |
|
Terminated
|
NCT04738292 -
Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)
|
Phase 2 |
|
Recruiting
|
NCT05982093 -
Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer
|
Phase 2 |
|
Recruiting
|
NCT05396612 -
Role of the Immune Environment in Response to Therapy in Breast Cancer
|
|
|
Recruiting
|
NCT04595565 -
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer
|
Phase 3 |
|
Terminated
|
NCT01234532 -
Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery
|
Phase 2 |